CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Stock Rated "Moderate Buy" by Wall Street Brokerages

Key Points

• Wall Street sentiment is moderately bullish: Eight analysts give CAMP4 Therapeutics an average “Moderate Buy” rating, including six buys, one hold and one sell. The average 12-month price target is $9.71 versus the stock’s recent price of $3.91.
• The company reported weak financial results: CAMP4 posted a quarterly loss of $0.58 per share, missing the $0.24 consensus estimate, on revenue of $1.78 million. Analysts expect a full-year loss of approximately $0.57 per share.
• Insider and institutional activity was mixed: Insiders bought 46,031 shares worth $99,051 over the past three months but sold 593,613 shares valued at $2.5 million. Several major investors, including Jupiter Topco, 5AM Venture Management and BlackRock, established new positions.

CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $9.71.

A number of equities analysts have recently weighed in on the company. Cantor Fitzgerald reiterated an "overweight" rating on shares of CAMP4 Therapeutics in a research note on Tuesday. Chardan Capital reduced their price target on CAMP4 Therapeutics from $6.50 to $6.00 and set a "buy" rating for the company in a research note on Tuesday. Zacks Research raised CAMP4 Therapeutics from a "strong sell" rating to a "hold" rating in a report on Monday, August 17th. UBS Group set a $15.00 price objective on CAMP4 Therapeutics in a research report on Friday, August 14th. Finally, Weiss Ratings raised CAMP4 Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, September 17th.

CAMP4 Therapeutics Stock Performance

Shares of CAMP stock opened at $3.91 on Wednesday. The company has a market capitalization of $245.35 million, a price-to-earnings ratio of -1.69 and a beta of 0.27. The company has a 50-day simple moving average of $4.11 and a 200 day simple moving average of $4.29. CAMP4 Therapeutics has a 52 week low of $2.85 and a 52 week high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.34). The company had revenue of $1.78 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. Sell-side analysts forecast that CAMP4 Therapeutics will post -0.57 EPS for the current year.

Insider Activity at CAMP4 Therapeutics

In other CAMP4 Therapeutics news, Director Richard Young acquired 16,378 shares of the company's stock in a transaction on Monday, August 3rd. The stock was acquired at an average price of $1.65 per share, for a total transaction of $27,023.70. Following the purchase, the director directly owned 186,388 shares of the company's stock, valued at $307,540.20. This trade represents a 9.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Kelly Gold purchased 10,000 shares of the company's stock in a transaction dated Monday, August 31st. The stock was acquired at an average price of $3.96 per share, with a total value of $39,600.00. Following the completion of the transaction, the chief financial officer owned 10,000 shares of the company's stock, valued at $39,600. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have acquired 46,031 shares of company stock worth $99,051 and have sold 593,613 shares worth $2,504,037. 21.69% of the stock is currently owned by corporate insiders.

Institutional Trading of CAMP4 Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Jupiter Topco LLC bought a new stake in shares of CAMP4 Therapeutics during the 2nd quarter valued at approximately $27,581,000. 5AM Venture Management LLC bought a new position in CAMP4 Therapeutics in the 2nd quarter valued at approximately $25,647,928. Trails Edge Capital Partners LP acquired a new stake in CAMP4 Therapeutics in the second quarter valued at approximately $8,446,935. BlackRock Inc. bought a new stake in shares of CAMP4 Therapeutics during the second quarter worth $7,185,000. Finally, SummitTX Capital L.P. bought a new stake in shares of CAMP4 Therapeutics during the first quarter worth $1,497,000.

CAMP4 Therapeutics Company Profile

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases caused by insufficient expression of essential proteins. The company's approach is designed to increase the body's production of naturally occurring proteins by activating the transcription of specific genes, potentially addressing the underlying cause of disease rather than only treating symptoms.

CAMP4's technology platform uses RNA-based gene-activation therapeutics intended to target regulatory regions associated with disease-relevant genes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.